SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period

Lancet Rheumatol. 2022 Nov;4(11):e747-e750. doi: 10.1016/S2665-9913(22)00221-1. Epub 2022 Aug 23.

Laura Boekel¹, Yaëlle R Besten¹, Femke Hooijberg¹, Rosa Wartena¹, Maurice Steenhuis², Erik Vogelzang³, Maureen Leeuw¹, Sadaf Atiqi¹, Sander W Tas⁴, Willem F Lems^{1

5}, S Marieke van Ham^{2

6}, Filip Eftimov⁷, Eileen W Stalman⁷, Luuk Wieske^{7

8}, Taco W Kuijpers⁹, Alexandre E Voskuyl⁵, Ronald F van Vollenhoven⁴, Martijn Gerritsen¹, Charlotte Krieckaert¹, Theo Rispens², Maarten Boers^{1

10}, Mike T Nurmohamed^{1

5}, Gertjan Wolbink^{1

2}

¹ Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, location Reade, 1056 AB, Amsterdam, Netherlands.
² Department of immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, Amsterdam, Netherlands.
³ Department of Medical Microbiology and Infection Control, Amsterdam UMC, location AMC, Amsterdam, Netherlands.
⁴ Department of Rheumatology and Clinical Immunology, Amsterdam Rheumatology and Immunology Center, University of Amsterdam, Amsterdam, Netherlands.
⁵ Department of Rheumatology and Clinical Immunology, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, Netherlands.
⁶ Swammerdam Institute for Life Sciences, University of Amsterdam, Amsterdam, Netherlands.
⁷ Department of Neurology and Neurophysiology, Amsterdam Neuroscience, Amsterdam UMC, location AMC, University of Amsterdam, Amsterdam, Netherlands.
⁸ Department of Clinical Neurophysiology, St Antonius Hospital, Nieuwegein, Netherlands.
⁹ Department of Pediatric Immunology, Rheumatology and Infectious Disease, Amsterdam UMC, location AMC, University of Amsterdam, Amsterdam, Netherlands.
¹⁰ Department of Epidemiology and Data Science, Vrije Universiteit, Amsterdam UMC, Amsterdam, Netherlands.

No abstract available